BMJ1d
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Correspondence to Dr Dimitrios T Boumpas, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Joint Academic Rheumatology Program, National ...
BMJ1d
Immune cell multiomics analysis reveals contribution of oxidative phosphorylation to B-cell functions and organ damage of lupus
Correspondence to Dr Keishi Fujio, Department of Allergy and Rheumatology, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; fujiok-int{at}h.u-tokyo.ac.jp; Dr Yukiko Iwasaki, Department of Palliative ...
BMJ1d
The effects of structural damage on functional disability in psoriatic arthritis
Background Functional outcomes are central in patients with chronic inflammatory musculoskeletal diseases. In a secondary data analysis of the GO-REVEAL trial (NCT00265096), we investigated wether ...
BMJ2d
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
1 Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Amsterdam, The Netherlands Objectives Millions of patients worldwide are treated with therapeutic ...
BMJ2d
Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
2 Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands 3 Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, ...
BMJ2d
Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus
Correspondence to Professor Gabriela Riemekasten, Department of Rheumatology, University Hospital Schleswig-Holstein—Campus Lübeck, Ratzeburger Allee 160, Lübeck 23538, Germany; ...
BMJ2d
Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE
Correspondence to Dr Jens Y Humrich, Department of Rheumatology and Clinical Immunology, Charité—University Medicine Berlin, Charitéplatz 1, Berlin 10117, Germany; jens.humrich{at}charite.de Here we ...
BMJ2d
“Go upstream, young man”: lessons learned from the p38 saga
Division of Rheumatology, Allergy and Immunology, UC San Diego School of Medicine, La Jolla, California, USA Correspondence to Dr D Hammaker, UCSD School of Medicine, 9500 Gilman Drive, La Jolla, CA ...
BMJ2d
Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis
Correspondence to Prof Nicola Dalbeth, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1, New Zealand; n.dalbeth{at}auckland.ac.nz Objectives To ...
BMJ2d
Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
Objective CONCERTO was a randomised, double-blind, parallel-armed study of methotrexate (MTX) in combination with adalimumab to assess whether an increasing trend of efficacy and decreased safety ...
BMJ2d
Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis
1 Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 2 First Faculty of Medicine, Department of Rheumatology, Institute of ...
BMJ2d
Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies
Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan Method: Data sources were observational studies that examined the association between smoking ...